All In Biotech

Free tool

FAERS Monitor: Enspryng

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761149 or its brand name (Enspryng, Satralizumab). Reports on generic versions are filed under their own applications.

Reports

1,789

Serious

1,398

78% of reports

Hospitalization

705

Death reported

102

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • neuromyelitis optica spectrum disorder305
  • off label use176
  • urinary tract infection140
  • pneumonia114
  • covid-1975
  • no adverse event75
  • fatigue66
  • hypoaesthesia56
  • infection56
  • headache54
  • pain49
  • arthralgia46
  • muscular weakness44
  • optic neuritis39
  • sepsis37

Reports by year received

View as table
YearReports
20141
202012
2021130
2022210
2023343
2024373
2025403
2026317

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,370 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neuromyelitis optica spectrum disorderSignal3053437.93052.6808,403
optic neuritisSignal3950.737.11,843
urinary tract infectionSignal1409.78.21,086
covid-19Signal755.04.0240
no adverse eventSignal754.93.9229
muscular weaknessSignal444.63.4119
infectionSignal564.63.5153
hypoaesthesiaSignal564.43.4145
pneumoniaSignal1144.13.5273
sepsisSignal373.92.877
off label useSignal1762.42.1143
arthralgia461.31.03
headache541.00.80
fatigue661.00.80
pain490.90.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.